Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma
Open Access
- 1 December 2004
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 15 (12), 1848
- https://doi.org/10.1093/annonc/mdh479
Abstract
Zoledronic acid is a long-acting bisphosphonate used to decrease skeletal events in patients with multiple myeloma and bony metastasis. It is known to lead to asymptomatic hypocalcaemia, but symptomatic hypocalcaemia after its use is rarely reported [1]. We report a patient with multiple myeloma who developed symptomatic hypocalcaemia with zoledronic acid.This publication has 4 references indexed in Scilit:
- Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D DeficiencyJournal of Clinical Oncology, 2004
- Zoledronic AcidDrugs, 2003
- Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development programSeminars in Oncology, 2001
- A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 1999